WO2004024717A1 - キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 - Google Patents
キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 Download PDFInfo
- Publication number
- WO2004024717A1 WO2004024717A1 PCT/JP2003/011733 JP0311733W WO2004024717A1 WO 2004024717 A1 WO2004024717 A1 WO 2004024717A1 JP 0311733 W JP0311733 W JP 0311733W WO 2004024717 A1 WO2004024717 A1 WO 2004024717A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydro
- dissolved
- amine
- mixture
- pyrrolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to an isoquinoline derivative having a Rho kinase inhibitory action, and more particularly, to an isoquinoline derivative useful for treating a disease involving Rho kinase.
- Rh o is activated in response to signals from various cell membrane receptors, and activated Rh o via ROCK / Rho kinase, and further via the actomyosin system, smooth muscle contraction, cell motility, cell adhesion, cells Molecules of various cellular phenomena such as morphological changes (actin stress to fiber formation), cell division control (enhancement of cytokinesis and gene transcription activation), platelet aggregation, leukocyte aggregation, cell proliferation, carcinogenesis and cancer invasion It is clear that it functions as a switch.
- Smooth muscle contraction is deeply involved in conditions such as hypertension, angina, vasospasm (eg, cardiovascular and cerebral vasospasm), asthma, peripheral circulatory disorders, imminent premature birth, glaucoma, visual field stenosis, pollakiuria, and erectile dysfunction.
- Cell motility plays an important role in invasive metastasis of cancer, arteriosclerosis, retinopathy, immune response, etc.
- Cell adhesion is involved in metastasis of cancer, inflammation, autoimmune disease, morphological change of cell is brain function It is deeply involved in disorders, osteoporosis, bacterial infection, etc., and cell proliferation is deeply involved in cancer, arteriosclerosis, etc.
- Rh is deeply involved in various diseases.
- ROCK serine Z threonine kinase activated with activation of Rh
- ROCK I Japanese Patent Application Laid-Open No. 9-135683, T. Ishizaki et al., ⁇ J., Vol. 15). , No. 8, ⁇ 1885-1893 (1996)
- Rhokinase or ROCK II
- JP-A-10-111318, T. Matsui et al., EMBO J., Vol. 15, No. .9, pp2208-2216 (1996) which have been shown to be isozymes (O. Nakagawa et al., FEBS Let JP2003 / 011733
- ROCKZRho kinase inhibitory activity include trans-41-amino (alkyl) -11-pyridylcarbamoylcyclohexane compound (WO 90/05723), benzoamide compound (WO 95/28387), Y-27632 (Uehata, M., Ishizaki, T. et al .: ature, 389, pp990-994 (1997)), Fasudil hydrochloride (HA-1077, Asahi Kasei) marketed as a cerebral vasospasm inhibitor (Ono-Saito, N., Niki, I., Hidaka, H .: Pharmacol. Ther., Ppl23-131 (1999)).
- WO 98 Z 06433 discloses an ROCKZRho kinase inhibitor.
- WO 01/56988 discloses a nitrogen-containing compound having an activity of inhibiting the release of quinone.
- An object of the present invention is to provide a compound having a Rho kinase inhibitory action and useful for treating a disease mediated by Rho kinase.
- Another object of the present invention is to provide a pharmaceutical composition used for treating a disease mediated by Rh kinase.
- the present inventors have found that certain isoquinoline derivatives have extremely excellent Rh kinase inhibitory activity (Pharmacological Test Examples 1 and 3). The present inventors have also confirmed that this isoquinoline derivative is extremely effective in treating diseases mediated by Rh kinase (Pharmacological Test Examples 2, 4, and 5).
- the compounds according to the present invention are compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof. '''
- Q represents a cyclic group selected from a phenyl group, a pyridyl group, a pyrrolyl group, a phenyl group, and a furyl group, and one or two hydrogen atoms on the cyclic group are It may be substituted by a substituent selected from the group consisting of a halogen atom, a d-4 alkyl group, a nitro group, and an amino group, and p is 2 or 3.
- the pharmaceutical composition according to the present invention comprises the compound according to the present invention as an active ingredient. Detailed description of the invention
- alkyl refers to a straight or branched alkyl group.
- d-4alkyl include methyl, ethyl, 11-propyl, isopropyl, n-butyl, i-butyl, s-butyl, and t-butyl.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- Q is preferably phenyl, 2-cloh fenolene, 3-cloh fenolen, 4-cloh feninole, 4-phnoleolopheninole, 2,6-diphnolelofenenole, 2, 6 —Diclo-mouth feninole, 4-methinolefeninole, 4-isopropinolefeninole, 2-nitrofeninole, 3-nitrophenigre, 4-nitrofeninole, 4-chloro-2-trophenenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-aminophenyl, 3-aminophenyl, 4-aminophenyl, 2-amino-4-cyclophenol, 1H-2-pyrrolyl, 1H-3-pyrrolyl, 2- Represents a cyclic group selected from chloro, 3-chel, 2-furyl and 3-furyl, particularly preferably 3-nitrophenyl and 3-aminoph
- Preferred examples of the compound of the formula (I) include compounds wherein Q represents 3-trophenyl or 3-aminophenyl and p is 2.
- More preferred examples of the compound of the formula (I) include the following compounds.
- Particularly preferred compounds of the formula (I) include (3S) _N5— [1 1- (3-Aminobenzyl) tetrahydro 1H-3-pyrrolyl] 5-isoquinolineamine and (3R) -N5- [1- (3-aminobenzyl) tetrahydro-1H-3-pyrrolinole] 1-5- Isoquinolinamine and mixtures thereof.
- Acid addition salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, and nitric acid, or maleic acid, fumaric acid, malic acid, oxalic acid, tartaric acid, succinic acid, citric acid, acetic acid, lactic acid And salts with organic acids such as methanesulfonic acid, p-toluenesulfonic acid, and salicyl salts, and salts with amino acids such as lysine.
- inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, and nitric acid
- maleic acid fumaric acid, malic acid, oxalic acid, tartaric acid, succinic acid, citric acid, acetic acid, lactic acid
- organic acids such as methanesulfonic acid, p-toluenesulfonic acid, and salicyl salts
- amino acids such as
- acid addition salts can be converted to the corresponding free bases by a conventional method, for example, by reaction with sodium hydroxide, hydroxylated lime or the like. Furthermore, it can be a quaternary ammonium salt or a metal salt such as sodium, potassium, calcium, magnesium, and aluminum.
- compositions of the compound of formula (I) include hydrates.
- the compounds of formula (I) can exist in optical isomers, racemic or cis-trans isomers, and the compounds according to the invention embrace all these. These isomers can be isolated by a conventional method or can be produced by using each isomer raw material.
- the compounds according to the invention can be prepared according to the following scheme.
- a suitable protecting group eg, (3R) 1-(+)-13- (tert-butoxyamino) pyrrolidine
- alkyl chloride Q—CH 2 —C 1 eg, potassium carbonate
- deprotected eg, trifluoroacetic acid
- X when X is triflate, it can be obtained by reacting 5-hydroxyisoquinoline with trifluoromethanesulfonic anhydride) and toluene at 80 ° C in the presence of cesium carbonate. It can be prepared by adding catalytic amounts of palladium acetate and BINAP. '
- the compound according to the present invention can also be produced according to the method described in WOO 1/56988.
- Rho kinase inhibitory activity see pharmacological test examples 1 and 3.
- Rho kinase include hypertension, asthma (eg, bronchial asthma), angina, cerebral vasospasm, peripheral circulatory disturbance, premature labor, glaucoma, visual field stenosis, pollakiuria, cancer, cancer Infiltration, metastasis, arteriosclerosis, retinopathy, immune response, inflammation, autoimmune disease, cerebral dysfunction, osteoporosis, bacterial infection, chronic renal failure, chronic nephritis, diabetic nephropathy, IgA nephropathy, thrombus formation Associated diseases, rheumatism, erectile dysfunction and fibrosis.
- asthma eg, bronchial asthma
- angina cerebral vasospasm
- peripheral circulatory disturbance premature labor
- glaucoma glaucoma
- visual field stenosis pollakiuria
- cancer cancer Infiltration, metastasis, arteriosclerosis
- treatment of a Rho kinase mediated disease comprising administering to a mammal, including a human, a therapeutically effective amount of a compound according to the present invention, together with a pharmaceutically acceptable carrier.
- a mammal including a human
- a therapeutically effective amount of a compound according to the present invention together with a pharmaceutically acceptable carrier.
- the invention also provides the use of a compound according to the invention for the manufacture of a medicament for the treatment of a disease mediated by Rho kinase.
- R ho is activated by receiving signals from various cell membrane receptors, and it is clear that activated R ho functions in smooth muscle contraction via ROC KZR ho kinase, and further via the actomyosin system (K. Kimura et al., Science, Vol. 273, No. 5272, pp245-248 (1996); Kureishi et al., J. Biol. Chera., Vo1.272, No. 19, PP12257—60 (1997)). Smooth muscle contraction is deeply involved in conditions such as hypertension, angina, cerebral vasospasm, asthma, peripheral circulatory disturbance, premature labor, glaucoma, visual field narrowing, erectile dysfunction, and frequent urination (eg, hypertension: AP.
- smooth muscle contraction is deeply involved in conditions such as hypertension, angina, cerebral vasospasm, asthma, peripheral circulatory disturbance, premature labor, glaucoma, visual field narrowing, erectile dysfunction, and frequent urination (eg, hypertension: AP.
- ROCK / Rho kinase inhibitors have antihypertensive effects in spontaneous hypertensive rats (SHR), direnal hypertensive rats, and saline Deoxycorticosterone acetate rats (D0CA rats) (Uehata , M., Ishizaki, T. et al .: Nature, 389: 990-994, 1997).
- ROCK / Rho kinase inhibitor has a bronchodilator effect and an anti-asthmatic effect in isolated bronchi and bronchial asthma model animals (WO93 / 05021, WO95 / 2). 8 3 8 7).
- Rh kinase inhibitor dose-dependently suppresses the increase in bronchial resistance due to acetylcholine inhalation in a bronchial asthma model, and in a concentration-dependent manner suppresses PAF-induced chemotaxis in human peripheral blood eosinophils in vitro (Kunihiko Iizuka: Allergy, 47: 943, 1998, Kunihiko Iizuka, Akihiro Yoshii: Japanese Respiratory Journal, 37: 196, 1999). Rh kinase is also involved in leukocyte migration.
- ROCK / Rho kinase inhibitors are involved in carbachol-induced trabecular meshwork in egrets and magpies and in contraction of ciliary muscle in humans (egg) (M Honjo et al., Investigative Ophthalmology and Visual Science. 2001; 42: 137-144, T. Huki garni et al., Biochem Biophys Res Coramun. 2001 Oct 26; 288 (2): 296-300), Egret's eye It is known to lower the pressure (TO 00/09162, M. Waki et al., Current Eye Research 2001, Vol. 22, No. 6, pp. 470-474).
- ROCKZRho kinase inhibitors have a relaxing effect on rat penis corpus cavernosum in vitro and a potentiating effect on rat penis corpus cavernosum in vitro (Kanchan Chitaley et al., Ature Medicine, Vol.7, No.1, 1 19-122 (2001)).
- the compounds according to the invention have a leukocyte migration inhibitory action and a blood pressure lowering action (see Pharmacological Test Examples 2 and 5).
- the compounds according to the present invention may be used for the treatment of hypertension, asthma (eg, bronchial asthma), angina, cerebral vasospasm, peripheral circulatory disorders, imminent preterm birth, glaucoma, visual field stenosis, erectile dysfunction and pollakiuria. it can.
- Rh o is activated by receiving signals from various cell membrane receptors.
- Activated Rh o is activated via ROCKZRho kinase, and also via the actomyosin system, to cell motility, cell adhesion, and cell transformation (actin). (Stressed fiber formation), cells It functions as a molecular switch for cellular phenomena such as division control (enhancement of cytokinesis and gene transcription activation), cell proliferation, carcinogenesis and enhancement of cancer invasion (P. Keely et al., Trends Cell Biol. Vol. 8, No. 3, pplOl-6 (1998); K. Itoh et al., Nat. Med., Vol 5, N
- Cell motility plays an important role in cancer invasion / metastasis, arteriosclerosis, retinopathy, immune response, etc.
- Cell adhesion is cancer metastasis, inflammation, autoimmune disease, cell morphological changes are brain dysfunction, It is involved in the search for porosis, bacterial infection, etc., and cell proliferation is deeply involved in cancer, arteriosclerosis, etc. (Experimental Medicine Vol. 17, No. 7 (1999)).
- Rho is involved in proliferation in addition to cell morphology control, particularly in the progression of the G1 to S phases of the cell cycle (Yamamoto, M., Marui , N., Oncogene, 8: 1449-1455, 1993). Also, it has been discovered that oncogenes such as Dbl are Rho family GDP-GTP exchange factors (Hart, M.J., Eva, A., Nature, 354: 311-314, 1991). In addition, it was revealed that Rac and R ho are activated downstream of Ras signal transduction (Ridley, A. JT. & Hall, A .: Cell 1, 70: 401-410, 1992). .
- Rho are downstream of Ras and may be involved in malignant transformation of cells by Ras (Qui, RG, Chen, J., et al, Nature: 374: 457-459, 1995., Qui, RG, Chen, J., et al, Proc. Natl. Acad. Sc
- ROCK downstream of Rho regulates invasion through activation of the actomyosin system Yoshioka, K., Matsumura, F., J. Bio. 1. Chem., 273: 5146-5154, 1998. It has been shown that the ROCKZRho-K? Inhibitor (Y—276 32) suppresses these invasive movements by controlling the pathway from Rh to ROCK (Itoh, K. , Yoshioka, K., Nature Med., 5: 2 21-225, 1999).
- the compounds according to the invention can be used for the treatment of cancer, cancer invasion, metastasis, arteriosclerosis, retinopathy, immune response, inflammation, autoimmune diseases, cerebral dysfunction, osteoporosis, and bacterial infections.
- Rho is activated by receiving signals from various cell membrane receptors, and activated Rh is activated by ROCK / Rho kinase, and furthermore, cell adhesion and blood cell Involved in the migration.
- Cell adhesion and leukocyte migration are involved in inflammation, especially nephritis (Osamu Fujimoto, Kozo Kaibuchi, Journal of the Japanese Society of Internal Medicine, 1999; 88 (1); 148-54). .
- Rh is involved in nephritis via HGF, LDL, platelets, or Na-H exchange (Mol. Cell. Biol. 1995; 15 (2): 1110-22; J. Biol. Chera. 1999; 274 (43): 30361-4; J. Biol. Chem., 1999; 274 (40): 28293-300; EMB0 "J., 1998; 17 (16): 4712-22).
- HGF HGF
- LDL low-H exchange
- the compounds according to the invention have a proteinuria-improving effect (see pharmacological test example 4).
- the compounds according to the invention can be used for the treatment of chronic renal failure, chronic nephritis, diabetic nephropathy and IgA nephropathy.
- Rh is activated by receiving signals from various cell membrane receptors, and activated Rho is activated by Rh-kinase and further via the actomyosin system, such as platelet aggregation, leukocyte aggregation and leukocyte migration. It has been clarified that it functions as a molecular switch of the phenomenon (K. Naka et al., Blood, Vol. 90, No. 10, pp. 3736-42 (1977)). ⁇ Platelet aggregation, leukocyte aggregation, and leukocyte migration are deeply involved in thrombus, inflammation, fibrosis, etc. In fact, the compounds according to the invention have leukocyte migration inhibitory activity (see pharmacological test example 2).
- the compounds according to the present invention may be used for diseases related to inflammation, asthma, thrombosis (eg, myocardial infarction, cerebral infarction, atherosclerosis obstructive, thromboembolic, generalized vascular coagulation), rheumatism, and f Can be used to treat Izumi disease.
- thrombosis eg, myocardial infarction, cerebral infarction, atherosclerosis obstructive, thromboembolic, generalized vascular coagulation
- rheumatism eg, myocardial infarction, cerebral infarction, atherosclerosis obstructive, thromboembolic, generalized vascular coagulation
- rheumatism eg, rheumatism
- the pharmaceutical composition containing the compound according to the present invention as an active ingredient can be administered to humans and humans by any of oral and parenteral (for example, intravenous administration, intramuscular administration, subcutaneous administration, rectal administration, transdermal administration). Can be administered to other animals. Therefore, the pharmaceutical composition containing the compound according to the present invention as an active ingredient can be formulated into an appropriate dosage form according to the administration route.
- oral preparations include tablets, capsules, powders, granules, syrups, pills, troches, etc.
- Parenteral preparations include injections (solutions, suspensions, etc.) , Inhalants, suppositories, transdermal absorbents (eg, tapes), ointments, eye drops, eye ointments and the like.
- excipients include lactose, pudose, corn starch, sorbitol, and crystalline cellulose
- examples of disintegrants include starch, sodium alginate, gelatin powder, calcium carbonate, calcium citrate, and dextrin
- examples of binders include Dimethinoresenololose, polyvinyl alcohol, polyvinylinoleatenole, methylenoresenorelose, ethylcellulose, gum arabic, gelatin, hydroxypropylcellulose, polyvinylpyrrolidone, and lubricants such as talc and magnesium stearate , Polyethylene glycol, and hydrogenated vegetable oil.
- excipients such as sucrose, lactose, cellulose sugar, D-mannitol, maltitol, dextran, starches, agar, alginate, chitin, chitosan, pectin, tran gum, Gum arabic, selatin, collagen, casein, albumin, calcium phosphate, sorbitol Glycine, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, glycerin, polyethylene glycol, sodium hydrogencarbonate, magnesium stearate, talc and the like. Tablets are tablets coated with normal skin as needed, such as sugar-coated tablets. Enteric-coated tablets, film-coated tablets or two-layer tablets or multi-layer tablets can be prepared.
- animal fats oil, corn oil, castor oil, etc.
- mineral fats valine, white petrolatum, solid paraffin, etc.
- waxes jojoba oil, carnapa wax, beeswax, etc.
- Partially synthesized or totally synthesized glycerin fatty acid esters such as lauric acid, myristic acid, and palmitic acid
- Witebsol manufactured by Dynamit Nobel
- Pharmasol manufactured by NOF Corporation
- additives such as sodium chloride, glucose, sorbitole, glycerin, olive oil, propylene glycol, and ethyl alcohol can be used.
- a sterile aqueous solution such as physiological saline, isotonic solution, or oily solution such as sesame oil or soybean oil is used.
- a suitable suspending agent such as sodium carboxymethylcellulose, a nonionic surfactant, and a solubilizing agent such as benzyl benzoate or benzyl alcohol may be used in combination.
- an aqueous solution or an aqueous solution is used, and particularly, a sterile aqueous solution for injection can be used.
- Buffers borate buffer, acetate buffer, carbonate buffer, etc. are preferred for reducing irritation
- isotonic agents are preferred for reducing irritation
- solubilizing agents are preferred for reducing irritation
- preservatives thickeners
- chelating agents chelating agents
- ⁇ adjuster ⁇ is usually preferable to be adjusted to about 2 to 8.5
- various additives such as fragrance may be appropriately added.
- the content of the compound according to the present invention in the pharmaceutical composition varies depending on the dosage form, but is usually 0.1 to 100% by weight in the whole composition. /. Preferably, it is about 1 to 50% by weight.
- the dose is appropriately determined depending on the individual case in consideration of the patient's age, body weight, sex, difference in disease, degree of symptoms, etc., for example, about 1 to 50 mg. It can be administered once or several times a day.
- the crude product was packed in silica gel gel chromatography developed on a black hole form, and developed only on a black hole form to obtain an intermediate (1.1.25 g).
- the mixture was filtered through celite, the filtrate was separated into an organic layer and an aqueous layer, and the aqueous layer was extracted three times with ethyl acetate. Dry the combined organic layers over sodium sulfate and concentrate to give a crude product. I got something.
- the crude product was subjected to silica gel column chromatography developed on The mixture was packed and developed only with a black hole form to obtain an intermediate (15.6 g).
- the intermediate (3.70 g, 2 Ommo 1) and 5-aminoaminoquinoline (Aldrich, 2.48 g, 17 mmo 1) were dissolved in 10 Om 1 of acetic acid, and sodium sulfate (14.2 g, 10 Ommo 1) was dissolved. 1) was added, and the mixture was stirred at room temperature for 30 minutes.
- the reaction mixture was cooled to 0 ° C., and sodium triacetate hydride (Aldrich, 4.44 g, 2 Ommo 1) was added little by little, and the mixture was stirred at room temperature for 18 hours.
- tert-Butyl 3- (5-isoquinolinoleamino) -111-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lml-form of chloroform and 1 ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile. At room temperature, 1 ml of a solution of 3-cyclomouth benzyl chloride (40 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Putinole 3- (5-isoquinolylamino) 11-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) is dissolved in chlorophonolem lm 1, trifluoroacetic acid lm 1 is added, and room temperature is added. For 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile. At room temperature, 1 ml of a solution of benzene chloride (40 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) -111-pyrrolidine ethoxylate (intermediate 1) (62 mg, 0.20 mmo 1) is dissolved in 1 ml of chlorophonolem, and 1 ml of trifluoroacetic acid is dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- tert-Butyl 3- (5-isoquinolylamino) -111-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in 1 ml of croral form and 1 ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, '0.5 Ommo 1) was added and dissolved in acetonitrile. At room temperature, 1 ml of a solution of 2,6-difluorobenzyl chloride (40 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) -111-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) is dissolved in 1 ml of chlorophonolem, and 1 ml of trifluoroacetic acid is added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added, and the mixture was dissolved in acetoetrile lm1. . At room temperature, 1 ml of an acetone solution of 2,6-dichlorobenzyl chloride (49 mg, 0.25 mmol) was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lmonochlorofonolem, and 1 ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 4-methylbenzyl chloride (40 mg, 0.25 mmol) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Putinole 3- (5-isoquinolinoleamino) -1-pyrrolidinecanolepoxylate (intermediate 1) 62 mg, 0.2 Ommo 1) was dissolved in clonal form lml, and trifluoroacetic acid 1 ml was dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 4-isopropynolebenzyl chloride (42 mg, 0.25 mmo1) in acetone was added at room temperature. And the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in 1 ml of chlorophonolem, and trifluoroacetic acid 1 ⁇ 1 was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg , 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile. At room temperature, 1 ml of a solution of 2-nitrobenzyl chloride (43 mg, 0.25 mmol) in acetone was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) -111-pyrrolidine ethoxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lm l-form and 1 ml of trifluoroacetic acid Was added and stirred at room temperature for 3 hours.
- potassium carbonate (Wako Chemical, 69nig, 0.5 Ommo 1) was added and dissolved in 1 ml of acetone nitrile.
- 1 ml of a solution of 3_nitrobenzyl chloride (43 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lm l of cloguchi form, and 1 ml of trifluoroacetic acid was dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 412 trobenzyl chloride (43 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) -111-pyrrolidine ethoxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in 1 ml of cloper form and trifluoroacetic acid 1 m 1 was added and stirred at room temperature for 3 hours.
- potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile Im 1.
- 1 ml of a solution of 4-cyclopent-2-nitropendinolechloride (52 mg, 0.25 mmo 1) in aceto-tolyl was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) is dissolved in chlorophonolem (lml), and trifluoroacetic acid (1 ml) is added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added. And dissolved in acetone. At room temperature, 1 ml of a solution of 3-chloromethylpyridin (41 mg, 0.25 mmol) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 11-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) is dissolved in chlorohonolem lml, and trifluoroacetic acid 1 ml is added. The mixture was stirred at room temperature for 3 hours. After the reaction mixture was concentrated, potassium carbonate (Wako Chemical, 69mg, 0. 5 Ommo 1) was dissolved in pressurized forte Asetonitoriru l m 1.
- the reaction mixture was cooled to 0 ° C, and a 30% ammonia solution (1 ml) was added dropwise thereto.
- Ethyl acetate was added and filtered through celite.
- the filtrate was separated into an organic layer and an aqueous layer, and the aqueous layer was extracted twice with ethyl acetate.
- the combined organic layers were dried over sodium sulfate and concentrated to give a crude product.
- the product was further purified by alumina (alum inaoxide 90 neutral) column chromatography developed with chloroform M (10: 1) to give the title compound (20 mg, 0.063 mmo 1).
- tert-Butyl 3- (5-isoquinolylamino) -11-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lml-form form, and 1 ml of trifluoroacetic acid was dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 3-—trobenzyl chloride (43 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidine ethoxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in lm l-form and 1 m 1 of trifluoroacetic acid Was added and stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.50 mmol) was added and dissolved in acetonitrile lm1. At room temperature, 1 ml of a solution of 4-nitrobenzyl chloride (43 mg, 0.25 mmo 1) in acetonitrile was dropped at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-pyrrolidinecarboxylate (intermediate 1) (62 mg, 0.2 Ommo 1) was dissolved in cromal form lm l, and trifluoroacetic acid 1 ml was dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of acetonitrinole solution of 4-chloro-2-benzo-2-benzophenochloride (50 mg, 0.25 mmo 1) was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- the reaction mixture was cooled to 0 ° C, and a 30% ammonia solution (1 ml) was added dropwise thereto.
- Ethyl acetate was added and filtered through celite.
- the filtrate was separated into an organic layer and an aqueous layer, and the aqueous layer was extracted twice with ethyl acetate.
- the combined organic layers were dried over sodium sulfate and concentrated to give a crude product.
- the product was further purified by alumina (alumina oxide 90 neutral) column chromatography developed with chloroform / methanol (10: 1) to give the title compound (24 mg, 0.068 mmo 1).
- tert-Butyl 3- (5-isoquinolylamino) -1-piperidinecarboxylate (intermediate 2) (66 rag, 0.2 Ommo 1) was dissolved in lm l-cloform and 1 ml of trifluoroacetic acid Was added and stirred at room temperature for 3 hours.
- potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- 1 ml of a solution of 2-chloro mouth benzyl chloride (40 mg, 0.25 mmo 1) in acetone was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3- (5-isoquinolylamino) -1-piperidinecarboxylate (intermediate 2) (66 mg, 0.20 mmo 1) was dissolved in 1 ml of chloroform and 1 ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 3-benzyl benzyl chloride (40 mg 0.25 mmo 1) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- Example 23 N- (1-benzyl 3-piperidyl) -1-5-isoquinolylamine tert-butyl 3- (5-isoquinolinolinoleamino) -11-piperidinecanolepoxylate (intermediate 2) (66 mg, 0.2 Ommo 1) was dissolved in black hole form (lm1), trifluoroacetic acid (1 ml) was added, and the mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added, and the mixture was dissolved in acetonitrino lenole lm1.
- tert-Putinole 3- (5- ⁇ f soquinolylamino) 11-pyrrolidinecarboxylate (intermediate 1) (66 mg, 0.2 Ommo 1) is dissolved in chlorophonolem lml, trifluoroacetic acid 1 ml is added, and the mixture is added at room temperature. Stir for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added, and the mixture was dissolved in acetoetrile lm1.
- Example 26 N- (5-isoquinolinyl) -N- [1- (4-methylbenzyl) -13-piperidyl] -amine tert-Butyl 3- (5 ⁇ soquinolylamino) 1-1-piperidine alkoxylate (intermediate 2) (66 mg, 0.20 mmo 1) is dissolved in 1 ml of chloroform and 1 ml of trifluoroacetic acid is dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lxn 1.
- tert-Butyl 3- (5-isoquinolinoleamino) -1-piperidinecarboxylate (intermediate 2) (66 mg, 0.2 Ommo 1) is dissolved in lml-form of clostat and 1 ml of trifluoroacetic acid is dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo1) was added. And dissolved in aceto-tolyl lni 1.
- tert-Butyl 3- (5-isoquinolinoleamino) 1-1-piperidine propyloxylate (intermediate 2) (66 mg, 0.2 Ommo 1) is dissolved in cromal form lm l and trifluoroacetic acid lm 1 was added and stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical Co., 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile. At room temperature, 1 ml of a solution of 2-nitrobenzyl chloride (43 mg, 0.25 mmo 1) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- intermediate 2 66 mg, 0.2 Ommo 1
- potassium carbonate (Wako Chemical Co., 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- 2-nitrobenzyl chloride 43 mg, 0.
- tert-Butyl 3- (5-isoquinolylamino) -1-piperidine alkoxylate (intermediate 2) (66 mg, 0.20 mmo 1) was dissolved in cromal form lm l, and trifluoroacetic acid 1 m 1 was added and stirred at room temperature for 3 hours.
- potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- 1 ml of a solution of 3-nitrobenzyl chloride (43 mg, 0.25 mmo 1) in acetone was added dropwise at room temperature, and the mixture was further stirred for 1 to 8 hours.
- tert-Butyl 3- (5-isoquinoligreamino) 1-1-piperidinecarboxylate (intermediate 2) (66 mg, 0.20 mmo 1) was dissolved in lml-cloform form, and 1 ml of trifluoroacetic acid was dissolved. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 3-chloromethylpyridine (41 mg, 0.25 mmol) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- tert-Butyl 3_ (5-isoquinolylamino) 1-1-piperidinecarboxylate (intermediate 2) (66 mg, 0.2 Ommo 1) was dissolved in lml-cloform form, and 1 ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, potassium carbonate (Wako Chemical, 69 mg , 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, 1 ml of a solution of 4-chloromethylpyridine (41 mg, 0.25 mmol) in acetonitrile was added dropwise at room temperature, and the mixture was further stirred for 18 hours.
- the reaction mixture was cooled to 0 ° C, and a 30% ammonium solution (lni1) was added dropwise thereto.
- Ethyl acetate was added and filtered through celite.
- the filtrate was separated into an organic layer and an aqueous layer, and the aqueous layer was extracted twice with ethyl acetate.
- the combined organic layers were dried over sodium sulfate and concentrated to give a crude product.
- the product was further purified by anolemina (aluminaoide 90 neutral) developed with chloroform / methanol (10: 1) column chromatography to obtain the title compound (18 mg, 0.054 mmo1).
- Example 37 N5- [1- (4-aminobenzyl) -1-piperidyl] -15-isoquinolylamine-tert-butyl-3- (5_isoquinolinoleamino) -1-piperidinecarboxylate (intermediate 2) ( 66 mg, 0.2 Ommo 1) was dissolved in chlorophonorem (lml), trifluoroacetic acid (1 ml) was added, and the mixture was stirred at room temperature for 3 hours. Reaction mixture After concentration, potassium carbonate (Wako Chemical, 69 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- the reaction mixture was cooled to 0 ° C, and a 30% ammonia solution (1 ml) was added dropwise thereto.
- Ethyl acetate was added and filtered through celite.
- the filtrate was separated into an organic layer and an aqueous layer, and the aqueous layer was extracted twice with ethyl acetate.
- the combined organic layers were dried over sodium sulfate and concentrated to give a crude product.
- the product was further purified by columno-maltography using an alumina (aluminaoide 90 neutra1) column developed with chloroform Z methanol (10: 1) to give the title compound (18 mg, 0.049 mmo1). :.
- the intermediate was dissolved in tetrahydrofuran (1 ml), and a borane-tetrahydrofuran complex (Kanto Chemical Co., Ltd., lmo 1/1, tetrahydrofuran solution) was dropped by 1 ml at 0 ° C. After stirring the reaction mixture at 60 for 3 hours, it was cooled to 0 ° C and 2 ml of a 1N aqueous hydrochloric acid solution was added dropwise. After further stirring at 60 ° C for 1 hour, a saturated aqueous sodium hydrogencarbonate solution (1 ml) was added, and the mixture was extracted with ethyl acetate.
- a borane-tetrahydrofuran complex Karlo Chemical Co., Ltd., lmo 1/1, tetrahydrofuran solution
- the intermediate was dissolved in tetrahydrofuran (1 ml), and 1 ml of a polan-tetrahydrofuran complex (Kanto Chemical, lmo 1/1, tetrahydrofuran solution) was dropped at 0 ° C. After the reaction mixture was stirred at 60 ° C for 3 hours, it was cooled to 0 ° C, and 2 ml of a 1 N aqueous hydrochloric acid solution was added dropwise. After further stirring at 60 ° C for 1 hour, a saturated aqueous sodium hydrogen carbonate solution (1 ml) was added, and the mixture was extracted with ethyl acetate.
- a polan-tetrahydrofuran complex Karlo Chemical, lmo 1/1, tetrahydrofuran solution
- tert-Putyl 3- (5-isoquinolylamino) 1-1-piperidine propyloxylate (intermediate 2) (66 mg, 0.2 Ommo 1) was dissolved in cromal form lm l, and trifluoroacetic acid 1 m 1 was added and the mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, diisopropylethylamine (65 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1.
- tert-Butyl 3- (5-isoquinolylamino) -1-piperidinecarboxylate (intermediate 2) (66 mg, 0.20 mmo1) was dissolved in lml-cloform form and 1 ml of trifluoroacetic acid was added. Was added and stirred at room temperature for 3 hours. After the reaction mixture was concentrated, diisopropylethylamine (65 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1.
- thiophene 3-canoleponic acid 32 mg, 0.25 mmo 1
- 1-ethynole 3- (3-dimethylaminopropyl) carbodiimide hydrochloride 5 lmg, 0.30 mmol
- 1-hydroxybenzotriazonole 46 mg, 0.30 mmol
- dimethylaminopyridine 2 mg
- tert-Butyl 3- (5-isoquinolinolenoamino)-1-piperidine carboxylate (intermediate 2) (66 mg, 0.20 mmo 1) was dissolved in Clolmform lm l, and trifluoroacetic acid 1 m 1 was added and stirred at room temperature for 3 hours. After concentrating the reaction mixture, diisopropylethylamine (65 mg, 0.5 Ommo 1) was added and dissolved in 1 ml of acetonitrile.
- tert-Butyl 3- (5-isoquinolylamino) 1-1-piperidine alkoxylate (intermediate 2) (66 mg, 0.20 mmo 1) is dissolved in chlorohonolem lm l, The mixture was stirred at room temperature for 3 hours. After concentrating the reaction mixture, diisopropylethylamine (65 mg, 0.5 Ommo 1) was added and dissolved in acetonitrile lm 1. At room temperature, furan-3-carbonic acid (32 mg, 0.25 mmo 1) was added, and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (51 mg, 0.30 mmo) was added.
- 5-Hydroisoquinoline (aldritch, 4.35 g, 3 Ommo 1) and pyridine (3.16 g) are dissolved in anhydrous chloroform (50 ml) and the mixture is dissolved at 0 ° C in trifluoromethanesulfonic acid (50 ml). 10 g, 35 mmo 1) were added dropwise. After stirring the reaction mixture for 3 hours, a saturated sodium hydrogen carbonate solution was added. The aqueous layer was extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated to give a crude product.
- Example 3 4 Example 35 Example 3 6
- Example 3 7 Example 3 8
- Example 3 9 Example 3 10
- Rh o kinases according to the disclosure of JP-A-1 0 1 1 3 1 8 7 No. incorporating c DN A encoding a fusion ⁇ white matter of the ⁇ shea R ho kinase catalytic region and glutathione S- transferase Baculovirus was prepared by infecting insect cells and producing them in insect cells. That together with the Rh o kinases 0 / position of phosphorous added AT P labeled with radioisotope (y 32 P- ATP) to the substrate (ribosoma 1 S 6 kinasesubstrate, S 6 2 3 1- 2 ⁇ 9) To phosphorylate the substrate. The substrate is radioisotope. Thereafter, the substrate was adsorbed on filter paper, and ATP was washed away with a phosphoric acid solution, and the amount of the phosphorylated substrate was measured by a liquid scintillation counter.
- radioisotope y 32 P- ATP
- Enzyme inhibitory activity of ⁇ compounds calculated the inhibition rate of phosphorylation of a substrate in advance by adding ⁇ sample prior to the enzyme reaction, IC 5 concentration at the time of 5 0 ° / 0 suppressed. Value.
- Human-derived histiocytic lymphoma (U937 / CCR2), which overexpresses mouse-derived CCR2, was suspended in 1-1-1 1640 medium containing 0.1% 83 containing test compound (5). X 10 6 / m 1) for 20 minutes. 24-hole plate Add MCP-1 ligand (1 ⁇ M) and a drug solution containing test compound (0.1% B?) ⁇ ]: 164 medium DMS O 1% to 5001 force [ I. On top of that, chemotaxel was placed and 200 ⁇ l of the above cell suspension was added to the upper layer, and allowed to migrate for 1 hour at 37 ° C. under 5% carbon dioxide gas. The number of cells that migrated to the lower chamber was counted using a particle counting analyzer (Cismettus CDA-500), and the migration inhibition rate was calculated by the following equation.
- Migration inhibition rate (%) (1 Number of migration when one test compound is added Z Number of migration when no test compound is added) X 100
- Inhibition rate (%) (1 amount of substrate when one test compound is administered Z amount of substrate when water is administered) X 100
- An anti-GBM antibody obtained by immunizing a rabbit with the rat-derived GBM fraction was administered to 8-week-old WKY male rats via the tail vein to induce nephritis.
- the hydrochloride salts of Examples 45 and 46 were dissolved in purified water and orally administered twice daily at a dose of 30 mg / kg for 3 days from 24 hours after the antibody administration.
- Urine was collected 24 hours after the antibody administration for 3 hours, and the amount of protein in the urine was measured.
- the following table shows the average value and standard error of the urinary protein amount of the six rats.
- Example 45 administration group 91.2 ⁇ 21.5
- Example 45 administration group 2.20 ⁇ 0.65
- Example 46 administration group 1.38 ⁇ 0.68
- anti-GBM antibody was injected into the tail vein of a 7-week-old WKY male rat at 7 weeks of age to induce nephritis.
- the following table shows the average value and standard error of the urinary protein levels of the six rats.
- Example 45 administration group 779.4 ⁇ 133.9
- Example 46 administration group 327.6 ⁇ 55.2
- Blood pressure decrease rate (%) ⁇ (blood pressure before compound administration-blood pressure after compound administration) Z Blood pressure before compound administration ⁇ X 100
- the blood pressure reduction rate shows the reduction rate and standard error of four SHRs.
- Test compound Blood pressure reduction rate (%) Example 45 10.2 ⁇ 3.1
- Example 46 25.1 ⁇ 4.4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004535967A JPWO2004024717A1 (ja) | 2002-09-12 | 2003-09-12 | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 |
US10/527,643 US7615564B2 (en) | 2002-09-12 | 2003-09-12 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
CA002502583A CA2502583A1 (en) | 2002-09-12 | 2003-09-12 | Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
EP03795435A EP1550660A1 (en) | 2002-09-12 | 2003-09-12 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
AU2003264427A AU2003264427A1 (en) | 2002-09-12 | 2003-09-12 | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
HK06103012A HK1082249A1 (en) | 2002-09-12 | 2006-03-08 | Isoquinoline derivatives having kinasae inhibitoryactivity and drugs containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-267077 | 2002-09-12 | ||
JP2002267077 | 2002-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004024717A1 true WO2004024717A1 (ja) | 2004-03-25 |
Family
ID=31986683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011733 WO2004024717A1 (ja) | 2002-09-12 | 2003-09-12 | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7615564B2 (ja) |
EP (1) | EP1550660A1 (ja) |
JP (1) | JPWO2004024717A1 (ja) |
CN (1) | CN100383140C (ja) |
AU (1) | AU2003264427A1 (ja) |
CA (1) | CA2502583A1 (ja) |
HK (1) | HK1082249A1 (ja) |
WO (1) | WO2004024717A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009518360A (ja) * | 2005-12-08 | 2009-05-07 | ナームローゼ・フエンノートチヤツプ・オルガノン | イソキノリン誘導体 |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
US7618984B2 (en) | 2005-08-30 | 2009-11-17 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
JP2009545544A (ja) * | 2006-08-03 | 2009-12-24 | ユニベルシテ ピエール エ マリー キュリー(パリ シズエム) | 原生動物寄生虫に関連する疾患の治療のためのrho/rock/pi3/aktキナーゼ阻害剤 |
US7655662B2 (en) | 2005-12-22 | 2010-02-02 | Alcon Research, Ltd. | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure |
JP2010513319A (ja) * | 2006-12-18 | 2010-04-30 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 細胞骨格活性rhoキナーゼインヒビター化合物、組成物及び使用 |
US7820670B2 (en) | 2006-12-21 | 2010-10-26 | Alcon Research, Ltd. | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
US8232292B2 (en) | 2007-07-02 | 2012-07-31 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
WO2007000240A1 (en) | 2005-06-28 | 2007-01-04 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
US7470787B2 (en) | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
BRPI0614063A2 (pt) | 2005-07-26 | 2011-03-09 | Sanofi Aventis | derivados de cicloexilamina isoquinolona |
AU2006274245B2 (en) | 2005-07-26 | 2011-11-24 | Sanofi-Aventis | Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20080064681A1 (en) * | 2006-09-11 | 2008-03-13 | Hiroyoshi Hidaka | Therapeutic agent for treating glaucoma |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
NZ577981A (en) | 2006-12-27 | 2011-12-22 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
BRPI0720909A2 (pt) | 2006-12-27 | 2016-11-01 | Sanofi Aventis | derivados de isoquinolina e isoquinolinona substituídos |
JP5318779B2 (ja) | 2006-12-27 | 2013-10-16 | サノフイ | シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体 |
EP2125745B1 (en) | 2006-12-27 | 2017-02-22 | Sanofi | Cycloalkylamine substituted isoquinolone derivatives |
CA2673920C (en) | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
EP2249837A4 (en) * | 2008-01-31 | 2011-06-15 | Univ Monash | METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES |
JP2011524912A (ja) * | 2008-06-18 | 2011-09-08 | インスパイアー ファーマシューティカルズ,インコーポレイティド | Rhoキナーゼ阻害化合物の眼科用製剤 |
US8158796B2 (en) * | 2008-06-18 | 2012-04-17 | Inspire Pharmaceuticals, Inc. | Process for the preparation of Rho-kinase inhibitor compounds |
KR101607090B1 (ko) | 2008-06-24 | 2016-03-29 | 사노피 | 6-치환된 이소퀴놀린 및 이소퀴놀리논 |
ES2541827T3 (es) | 2008-06-24 | 2015-07-27 | Sanofi | Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa |
US8524737B2 (en) | 2008-06-24 | 2013-09-03 | Sanofi | Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives |
US8410147B2 (en) * | 2008-06-26 | 2013-04-02 | Inspire Pharmaceuticals, Inc. | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds |
US8207195B2 (en) * | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
US8299096B2 (en) | 2008-06-26 | 2012-10-30 | Inspire Pharmaceuticals, Inc. | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
US20100008968A1 (en) * | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2737738A1 (en) * | 2008-09-18 | 2010-03-25 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
EP2400969A4 (en) * | 2008-12-04 | 2012-05-16 | Inspire Pharmaceuticals Inc | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITORY COMPOUNDS |
ES2672624T3 (es) | 2009-05-01 | 2018-06-15 | Aerie Pharmaceuticals, Inc. | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
FI3811943T3 (fi) | 2013-03-15 | 2023-04-14 | Aerie Pharmaceuticals Inc | Yhdiste käytettäväksi silmäsairauksien hoidossa |
CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CN108601355B (zh) | 2015-11-17 | 2021-03-30 | 爱瑞制药公司 | 制备激酶抑制剂及其中间体的方法 |
CN109640966A (zh) | 2016-08-31 | 2019-04-16 | 爱瑞制药公司 | 眼用组合物 |
CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006433A1 (fr) * | 1996-08-12 | 1998-02-19 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE |
WO2001056988A1 (fr) * | 2000-02-01 | 2001-08-09 | Kirin Beer Kabushiki Kaisha | Composes contenant de l'azote et possedant une activite d'inhibition des kinases, et medicaments comprenant ces composes |
-
2003
- 2003-09-12 CA CA002502583A patent/CA2502583A1/en not_active Abandoned
- 2003-09-12 US US10/527,643 patent/US7615564B2/en not_active Expired - Fee Related
- 2003-09-12 AU AU2003264427A patent/AU2003264427A1/en not_active Abandoned
- 2003-09-12 CN CNB038250977A patent/CN100383140C/zh not_active Expired - Fee Related
- 2003-09-12 EP EP03795435A patent/EP1550660A1/en not_active Withdrawn
- 2003-09-12 WO PCT/JP2003/011733 patent/WO2004024717A1/ja active Application Filing
- 2003-09-12 JP JP2004535967A patent/JPWO2004024717A1/ja active Pending
-
2006
- 2006-03-08 HK HK06103012A patent/HK1082249A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998006433A1 (fr) * | 1996-08-12 | 1998-02-19 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE |
WO2001056988A1 (fr) * | 2000-02-01 | 2001-08-09 | Kirin Beer Kabushiki Kaisha | Composes contenant de l'azote et possedant une activite d'inhibition des kinases, et medicaments comprenant ces composes |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618984B2 (en) | 2005-08-30 | 2009-11-17 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
JP2009518360A (ja) * | 2005-12-08 | 2009-05-07 | ナームローゼ・フエンノートチヤツプ・オルガノン | イソキノリン誘導体 |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
US7655662B2 (en) | 2005-12-22 | 2010-02-02 | Alcon Research, Ltd. | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure |
JP2009545544A (ja) * | 2006-08-03 | 2009-12-24 | ユニベルシテ ピエール エ マリー キュリー(パリ シズエム) | 原生動物寄生虫に関連する疾患の治療のためのrho/rock/pi3/aktキナーゼ阻害剤 |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
JP2010513319A (ja) * | 2006-12-18 | 2010-04-30 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 細胞骨格活性rhoキナーゼインヒビター化合物、組成物及び使用 |
AU2007333715B2 (en) * | 2006-12-18 | 2013-01-10 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US7820670B2 (en) | 2006-12-21 | 2010-10-26 | Alcon Research, Ltd. | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US8232292B2 (en) | 2007-07-02 | 2012-07-31 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
US8664243B2 (en) | 2007-07-02 | 2014-03-04 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
Also Published As
Publication number | Publication date |
---|---|
US20060167043A1 (en) | 2006-07-27 |
AU2003264427A1 (en) | 2004-04-30 |
CA2502583A1 (en) | 2004-03-25 |
CN1694879A (zh) | 2005-11-09 |
CN100383140C (zh) | 2008-04-23 |
JPWO2004024717A1 (ja) | 2006-01-05 |
HK1082249A1 (en) | 2006-06-02 |
US7615564B2 (en) | 2009-11-10 |
EP1550660A1 (en) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004024717A1 (ja) | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 | |
ES2377556T3 (es) | Compuestos que contienen nitrógeno, que tienen actividad inhibitoria quinasa, y composiciones farmacéuticas que los comprenden | |
AU2017281439B2 (en) | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | |
KR102090780B1 (ko) | 혈전색전성 질환의 치료를 위한 인자 xia 억제제로서 치환된 피롤리딘 | |
US5321034A (en) | Fibrinogen receptor antagonists | |
WO2006126676A1 (ja) | 置換アルキル基を有する環状アミン誘導体 | |
AU655876B2 (en) | 1-{2-(arylsulphonylamino)-1-oxoethyl}piperidine derivatives, their preparation and their therapeutic application | |
IL103613A (en) | VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them. | |
JP2005528406A (ja) | 三環式トロンビンレセプターアンタゴニスト | |
EA021119B1 (ru) | Карбоксамидные соединения для лечения метаболических расстройств | |
EA018616B1 (ru) | Ингибиторы протеина, активирующего 5-липоксигеназу (flap) | |
BRPI0617166A2 (pt) | derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão | |
AU2015291477B2 (en) | Novel 2,5-substituted pyrimidines as PDE inhibitors | |
JP2005232175A (ja) | 5−置換イソキノリン医薬 | |
CN101379059A (zh) | N-羟基丙烯酰胺化合物 | |
US20210040066A1 (en) | Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof | |
JP5778133B2 (ja) | シクロプロパンカルボン酸誘導体 | |
JP2012511514A (ja) | レニン阻害剤としての3,4−置換ピペリジン誘導体 | |
US8193218B2 (en) | Aroyl-piperidine derivatives and method of treating disorders induced by substance P | |
CZ20023460A3 (en) | Protease inhibitors | |
EP1346994A1 (en) | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | |
JP4831908B2 (ja) | Tnf阻害活性を有するフェニル−およびピリジル−テトラヒドロピリジン類 | |
US20040229863A1 (en) | Protease inhibitors | |
RU2792034C2 (ru) | Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение | |
JP2001504798A (ja) | アレルギー疾患の治療に有用な新規な置換されたn―メチル―n―(4―(4―(1h―ベンズイミダゾール―2―イル―アミノ)ピペリジン―1―イル)―2―(アリール)ブチル)ベンズアミド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004535967 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003795435 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2502583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038250977 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003795435 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006167043 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10527643 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10527643 Country of ref document: US |